A Prospective Cohort Study on Colorectal Cancer Screening in Community Population
Recruiting · NCT05485077 · Observational (researchers observe without assigning treatment) · Lead sponsor: Singlera Genomics Inc.
View the official record on ClinicalTrials.gov →What this trial is about
This study will validate the real world results of polygene methylation detection in colorectal cancer in a large prospective community cohort. In this study, questionnaire survey and polygene methylation detection technology of colorectal cancer were used as preliminary screening methods, and colonoscopy was used as further validation examination method to screen colorectal cancer and precancerous lesions. The diagnosis and outcome of all lesions were based on colonoscopy and pathological examination.
Who can take part
Age range
40 Years and older
Sex
All (male and female)
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Chronological age ≥40 years;
- Full capacity for action;
- After enrollment, the participants were able to complete the Colorectal Cancer Risk Factor Assessment Questionnaire and the annual follow-up interviews;
- In the course of the study, the information related to tumor diagnosis in other hospitals can be timely fed back to the researchers;
Exclusion criteria
- History of colorectal cancer and other malignant tumors;
- Previous colorectal resection;
- undergoing any cancer-related treatment;
- Patients who have received major surgical treatment such as blood transfusion or transplantation within 3 months;
- Participate in other interventional clinical investigators within 3 months;
- Pregnant or lactating women;
- Have autoimmune disease, hereditary disease, mental illness/disability, etc
- Poor compliance, unable to complete the study.
Where it is running
1 location listed.
- Peking University Shougang Hospital - Beijing, Beijing Municipality, China